ResearcherUniversity of PennsylvaniaActive in the last 2 years

Emily J. Anstadt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8426-6540; OpenAlex author ID A5030212782. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper

Papers 1

SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.35058 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

John Peter Plastaras · 1 shared paper, 2024 · strength 0.18
- Paper SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcin… DOI 10.1002/cncr.35058 ↗
Edgar Ben‐Josef · 1 shared paper, 2024 · strength 0.18
- Paper SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcin… DOI 10.1002/cncr.35058 ↗
Nikhil Yegya‐Raman · 1 shared paper, 2024 · strength 0.18
- Paper SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcin… DOI 10.1002/cncr.35058 ↗
James M. Metz · 1 shared paper, 2024 · strength 0.18
- Paper SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcin… DOI 10.1002/cncr.35058 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.